Allegria Therapeutics secures USD 3.5 million Seed Financing to drive innovation in mast cell-mediated disease treatment

Allegria Therapeutics, a Swiss Biotech startup pioneering treatments for mast cell-mediated diseases, announces securing Seed Funding to advance its pipeline. This key investment coincides with Allegria's participation in the Swiss National Biotech Startup Team 2024 roadshow, currently underway in Boston, where the ten selected startups are connecting with potential investors and business partners.

Allegria Therapeutics' R&D activities focus on mast cells as mediators of allergy and inflammatory diseases, a class of indications that constitutes an increasing burden worldwide. More and more patients suffer from these conditions' impact on their quality of life. The associated socioeconomic burden is huge, and despite the growing medical need, the treatment options are still notoriously limited with overall poor outcomes.

Today, the startup—currently on a business development and investor roadshow in Boston with the Venture Leaders Biotech—announced a Seed Financing round of USD 3.5 million led by Forty51 Ventures, with Maria van Dongen, PhD, appointed as CEO. Dr. van Dongen's extensive industry experience includes notable roles at Johnson & Johnson, driving collaborations for RNA processing and peptide-based therapeutics.

With this funding, Allegria aims to advance its portfolio of innovative therapeutic approaches targeting mast cells, collaborating with esteemed partners such as Prof. Marcus Maurer and Dr. Philipp Starkl.